Terms: = Pancreatic cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568
170 results:
1. Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
[TBL] [Abstract] [Full Text] [Related]
2. il-2 promotes expansion and intratumoral accumulation of tumor infiltrating dendritic cells in pancreatic cancer.
Gong T; Huang X; Wang Z; Chu Y; Wang L; Wang Q
Cancer Immunol Immunother; 2024 Mar; 73(5):84. PubMed ID: 38554155
[TBL] [Abstract] [Full Text] [Related]
3. Infiltration of CD3+ and CD8+ lymphocytes in association with inflammation and survival in pancreatic cancer.
Tushoski-Alemán GW; Herremans KM; Underwood PW; Akki A; Riner AN; Trevino JG; Han S; Hughes SJ
PLoS One; 2024; 19(2):e0297325. PubMed ID: 38346068
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
Amaria R; Knisely A; Vining D; Kopetz S; Overman MJ; Javle M; Antonoff MB; Tzeng CD; Wolff RA; Pant S; Lito K; Rangel K; Fellman B; Yuan Y; Lu KH; Sakellariou-Thompson D; Haymaker CL; Forget MA; Hwu P; Bernatchez C; Jazaeri AA
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309721
[TBL] [Abstract] [Full Text] [Related]
5. Overcoming immune checkpoint blockade resistance in solid tumors with intermittent ITK inhibition.
Zhao M; Li L; Kiernan CH; Castro Eiro MD; Dammeijer F; van Meurs M; Brouwers-Haspels I; Wilmsen MEP; Grashof DGB; van de Werken HJG; Hendriks RW; Aerts JG; Mueller YM; Katsikis PD
Sci Rep; 2023 Sep; 13(1):15678. PubMed ID: 37735204
[TBL] [Abstract] [Full Text] [Related]
6. Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids.
Beelen NA; Aberle MR; Bruno V; Olde Damink SWM; Bos GMJ; Rensen SS; Wieten L
Front Immunol; 2023; 14():1133796. PubMed ID: 37520563
[TBL] [Abstract] [Full Text] [Related]
7. Expression of miR-425-5p in pancreatic Carcinoma and Its Correlation with Tumor Immune Microenvironment.
Jian S; Kong D; Tian J
J Invest Surg; 2023 Dec; 36(1):2216756. PubMed ID: 37455016
[No Abstract] [Full Text] [Related]
8. Transformation of immunosuppressive mtKRAS tumors into immunostimulatory tumors by Nerofe and Doxorubicin.
Ohana J; Sandler U; Devary O; Devary Y
Oncotarget; 2023 Jul; 14():688-699. PubMed ID: 37395796
[TBL] [Abstract] [Full Text] [Related]
9. Combinatorial immunotherapy with gemcitabine and ex vivo-expanded NK cells induces anti-tumor effects in pancreatic cancer.
Koh EK; Lee HR; Son WC; Park GY; Kim J; Bae JH; Park YS
Sci Rep; 2023 May; 13(1):7656. PubMed ID: 37169953
[TBL] [Abstract] [Full Text] [Related]
10. IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer.
Lutz MS; Zekri L; Weßling L; Berchtold S; Heitmann JS; Lauer UM; Jung G; Salih HR
Front Immunol; 2023; 14():1163136. PubMed ID: 37122707
[TBL] [Abstract] [Full Text] [Related]
11. Simultaneous targeting of PD-1 and il-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis.
Piper M; Hoen M; Darragh LB; Knitz MW; Nguyen D; Gadwa J; Durini G; Karakoc I; Grier A; Neupert B; Van Court B; Abdelazeem KNM; Yu J; Olimpo NA; Corbo S; Ross RB; Pham TT; Joshi M; Kedl RM; Saviola AJ; Amann M; Umaña P; Codarri Deak L; Klein C; D'Alessandro A; Karam SD
Cancer Cell; 2023 May; 41(5):950-969.e6. PubMed ID: 37116489
[TBL] [Abstract] [Full Text] [Related]
12. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma.
Chen Y; Lin X; Zou X; Qian Y; Liu Y; Wang R; Wang X; Yu X; Liu C; Cheng H
BMC Gastroenterol; 2023 Apr; 23(1):113. PubMed ID: 37024802
[TBL] [Abstract] [Full Text] [Related]
13. Chlorin e6-associated photodynamic therapy enhances abscopal antitumor effects via inhibition of PD-1/PD-L1 immune checkpoint.
Gurung P; Lim J; Shrestha R; Kim YW
Sci Rep; 2023 Mar; 13(1):4647. PubMed ID: 36944686
[TBL] [Abstract] [Full Text] [Related]
14. Combined phospholipids adjuvant augments anti-tumor immune responses through activated tumor-associated dendritic cells.
Shui Y; Hu X; Hirano H; Tsukamoto H; Guo WZ; Hasumi K; Ijima F; Fujino M; Li XK
Neoplasia; 2023 May; 39():100893. PubMed ID: 36893559
[TBL] [Abstract] [Full Text] [Related]
15. Synchronous or metachronous presentation of pancreatic neuroendocrine tumor versus secondary lesion to pancreas in patients affected by renal cell carcinoma. Systematic review.
Persano I; Parlagreco E; La Salvia A; Audisio M; Volante M; Buttigliero C; Scagliotti GV; Brizzi MP
Semin Oncol; 2022 Dec; 49(6):476-481. PubMed ID: 36759234
[TBL] [Abstract] [Full Text] [Related]
16. TGF-β2 antisense oligonucleotide enhances T-cell mediated anti-tumor activities by il-2 via attenuation of fibrotic reaction in a humanized mouse model of pancreatic ductal adenocarcinoma.
Lee HK; Nam MW; Go RE; Koo J; Kim TH; Park JE; Choi KC
Biomed Pharmacother; 2023 Mar; 159():114212. PubMed ID: 36610224
[TBL] [Abstract] [Full Text] [Related]
17. Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer.
Heiduk M; Plesca I; Glück J; Müller L; Digomann D; Reiche C; von Renesse J; Decker R; Kahlert C; Sommer U; Aust DE; Schmitz M; Weitz J; Seifert L; Seifert AM
JCI Insight; 2022 Nov; 7(22):. PubMed ID: 36509285
[TBL] [Abstract] [Full Text] [Related]
18. Mesothelin CAR-T cells secreting PD-L1 blocking scFv for pancreatic cancer treatment.
Wang Y; Fang X; Li M; Ye J; Zhao S; Yu L; Wang J; Wang Y; Yan Z
Cancer Genet; 2022 Nov; 268-269():103-110. PubMed ID: 36288641
[TBL] [Abstract] [Full Text] [Related]
19. Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4.
Hao S; Xu S; Li L; Li Y; Zhao M; Chen J; Zhu S; Xie Y; Jiang H; Zhu J; Wu M
BMC Cancer; 2022 Oct; 22(1):1092. PubMed ID: 36284271
[TBL] [Abstract] [Full Text] [Related]
20. The Additional Diagnostic Benefit of pancreatic cancer Molecular Profiling After Germline Testing.
Walker EJ; Blanco AM; Carnevale J; Cinar P; Collisson EA; Tempero MA; Ko AH
Pancreas; 2022 Apr; 51(4):302-304. PubMed ID: 35695740
[TBL] [Abstract] [Full Text] [Related]
[Next]
